Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 253-446-5 | CAS number: 37288-54-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The acute oral and acute inhalation toxicity of mannanase has been tested. Both studies were short-term toxicity tests conducted according to OECD guidelines and in compliance with GLP. No acute dermal toxicity test was conducted. The conclusion was that mannanase is non-toxic by acute oral or inhalation exposure. Based on weight of evidence, mannanase does not exert any acute dermal toxicity under foreseeable realistic exposures for either workers or consumers.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From January 21, 1991 to August 29, 1991
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 (Acute Toxicity (Oral))
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Source: Charles River U.K. Limited, Margate, Kent, England.
- Fasting period before dosing: Overnight prior to and approximately 4 hours after dosing.
- Housing: Five animals per cage, metal cages with wire mesh floors.
- Weight at time of dosing: Between 114-134 grams
- Housing: In animal room with control of temperature and humidity
- Diet: Standard diet ad libitum
- Water: Tap water ad libitum
- Acclimation period: 8 days
- Temperature (°C): 20-22°C
- Humidity: 68% (mean daily relative humidity value) - Route of administration:
- oral: gavage
- Vehicle:
- other: Distilled water
- Details on oral exposure:
- Diluted at a concentration of 50% w/v in distilled water.
- Doses:
- 3.32 g total protein/kg bogyweight, 10 mL/kg bodyweight
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days after dosing
- Frequency of observations and weighing: soon after dosing, every 5 hours for the remainder of the day of dosing, twice a day for the rest of the study period. Weighing on Day of dosing (Day 1), Day 8, and Day 15.
- Necropsy of survivors performed: yes (macroscopic post mortem examination) - Statistics:
- No
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 3.32 other: g/kg bw
- Based on:
- other: Total protein
- Mortality:
- Male: 5 g/kg bw; Number of animals: 5; Number of deaths: 0
Female: 5 g/kg bw; Number of animals: 5; Number of deaths: 0 - Clinical signs:
- other: Pilo-erection was observed in all rats within two minutes after dosing and throughout the remainder of Day 1 (day of dosing). No clinical signs were observed by Day 2.
- Gross pathology:
- Effects on organs:
No treatment related findings were observed. Histopathology was not performed. - Interpretation of results:
- study cannot be used for classification
- Conclusions:
- In conclusion, the acute oral lethal dosage (LD50) to rats of the present Mannanase enzyme, Mannase EM, was greater than 3.32 g total protein/kg bw.
- Executive summary:
The study was performed according to GLP and the procedures were according to EEC Methods for the determination of toxicity, Directive 84/449/EEC (OJ No. L251, 19.09.84), Part B, Method B.1. Acute Toxicity (oral).
The test item was supplied as a beige powder and was prepared at a concentration of 50% w/v in distilled water. The dose volume administered was 10 mL/kg.
The only clinical sign observed was piloerect coat in all rats within two minutes after dosing and throughout the remainder of Day 1 (day of dosing). No clinical signs were observed by Day 2. The overall body weight gain during the study was considered to be normal. The post-mortem inspection revealed no abnormalities.
In conclusion, the acute lethal oral dose to rats of the present mannanase enzyme, Mannase EM, was found to be greater than 3.32 g total protein/kg bw.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Value:
- 3 320 mg/kg bw
- Quality of whole database:
- Toxicological data has been generated within the enzyme producing industry during the last 40 years. Substantial documentation on the safety of the production strains have been generated, and the enzyme test materials are thoroughly characterized. High quality studies for all relevant endpoints, in vivo studies as well as in vitro studies, show that industrial enzymes from well-known and well-characterized production strains have very similar safety profiles across the catalytic activities. Read-across can therefore be applied for the majority of toxicological endpoints. The database can thus be considered of high quality.
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From August 16, 1999 to November 30, 1999
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- other: EEC, OECD and US EPA (Health Effects Test Guidelines, OPPTS 870, 1300, Acute Inhalation Toxicity, 5 August 1998) and JMAFF test guidelines for acute inhalation studies
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Source: Charles River UK Ltd, Manston Road, Margate, Kent UK.
- Housing: Five animals per cage
- Housing: In holding cages (size 35 cm x 53 cm x 25 cm height) in animal room with control of temperature and humidity
- Diet: SDS rat and mouse diet (RM1), ad libitum, except during the 4 hr exposure
- Water: Tap water ad libitum, except during the 4 hr exposure
- Acclimation period: 8 days
- Temperature (°C): 20-26°C
- Humidity: 44-66 % - Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- nose only
- Vehicle:
- air
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: ADG Developments Ltd., Hitchin, Hertfordshire, England
- Exposure chamber volume: 30 L
- Method of holding animals in test chamber: Snout only
- Source and rate of air: A supply of clean dried air was connected to the aerosol generator and the supply pressure was adjusted to give a flow rate of 15 litres/minute measured at the outlet of the generator. An in-line flow meter was used to monitor airflow throughout the exposure.
- Method of conditioning air: Filtered, oil-free compressed air for the production of the test atmosphere was supplied by compressors.
- System of generating particulates/aerosols: The test substance was supplied to the generator via the feed line from a syringe driven at a constant rate by a syringe pump (Precidor® type 5003).
- Method of particle size determination: Two air samples were taken during the exposure at a sampling rate of 2 L/minute using a Marple cascade impactor (Model 296, Graseby Andersen Inc., Atlanta, USA) to determine particle size distribution. The volume of air sampled was measured using a wet-type gas meter (Model DM3B, G. H. Seal Ltd., London, England).
- Temperature, humidity, pressure in air chamber: Mean temp: 19.9°C (control group) and 19.6°C (test group), relative humidity: 49% (control group) and 95% (test group).
TEST ATMOSPHERE
- Brief description of analytical method used: Seven air samples were taken during exposure. Chamber air was drawn at a measured rate of 2 L/minute, through a pre- weighed glass fibre filter (Whatman GF/A) mounted in an open face filter holder. Filters were dried for 15 minutes in an oven at 30-35°C, and then re-weighed for gravimetric analysis of the test aerosol.
TEST ATMOSPHERE
- Particle size distribution: 87% respirable (< 7 µm in aerodynamic diameter) - Analytical verification of test atmosphere concentrations:
- yes
- Duration of exposure:
- >= 4 h
- Concentrations:
- 0.45 mg enzyme concentrate dry matter/L
- No. of animals per sex per dose:
- 5
- Control animals:
- yes
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observations for clinical signs of effect: At the end of the chamber equilibration period, at 0.25, 0.5 and 1.0 hours then at hourly intervals during the exposure, immediately following completion of the exposure and then at 1.0 and 2.0 hours post-exposure. Subsequent, daily observations. Body weight: Just before exposure and weekly during the observation period.
- Necropsy of survivors performed: yes
- Other examinations performed: Organ weights: The lungs, liver and kidneys of each animal were weighed. - Statistics:
- Not performed.
- Key result
- Sex:
- male/female
- Dose descriptor:
- LC50
- Effect level:
- > 0.45 mg/L air (analytical)
- Based on:
- other: Enzyme concentrate dry matter
- Exp. duration:
- 4 h
- Mortality:
- No mortality.
- Clinical signs:
- other: No clinical signs. Fur/skin soiled with excreta was observed in all test and control rats immediately after exposure, but was not present 1 hour later. Brown staining on the head was seen in 2 male and female control rats and 2 male test rats up to 1 hour
- Body weight:
- The mean bodyweight gain for male test rats was 69 g compared with 47 g for control rats during the 14-day observation period; however, all body weights and body weight gains were within the expected range throughout the study.
- Gross pathology:
- No abnormalities.
- Other findings:
- The mean liver weight of test males was higher (+14%) than the control values. This was considered to be associated with the slightly heavier bodyweights of the test rats.
- Interpretation of results:
- study cannot be used for classification
- Conclusions:
- There were no unscheduled deaths or evidence of a toxic response following exposure of rats for 4 hours to a droplet aerosol generated from Mannanase, PPE 6432 at a chamber concentration of 0.45 mg enzyme concentrate dry matter/L.
- Executive summary:
The present study was performed in rats, in accordance with GLP and in compliance with EEC, OECD and US EPA (Health Effects Test Guidelines, OPPTS 870, 1300, Acute Inhalation Toxicity, 5 August 1998) and JMAFF test guidelines for acute inhalation studies. One control group and one test group each consisting of 5 females and 5 males were included.
The animals in the test group were exposed by snout-only exposure for 4 hours to air containing a liquid droplet aerosol generated from the test substance, Mannanase, PPE 6432, at a concentration of 0.45 mg enzyme concentrate dry matter/L. Mass median aerodynamic diameter and percentage of particles < 7 µm of Mannanase, PPE 6432, were 2.9 µm and 87%, respectively.
The animals were observed during exposure, for two hours after the exposure and daily during the 14-day observation period. After the observation period, the animals were sacrificed and examined pathologically.
Fur/skin soiled with excreta was observed in all test and control rats immediately after exposure, but was not present 1 hour later. Brown staining on the head was seen in 2 male and female control rats and 2 male test rats up to 1 hour after exposure. These were temporary signs and were considered to be associated with the tube restraint for inhalation exposure.
The mean bodyweight gain for male test rats was 69 g compared with 47 g for control rats during the 14-day observation period; however, all body weights and body weight gains were within the expected range throughout the study period. Moreover, the mean liver weight of test males was higher (+14%) than the control values. This was considered to be associated with the slightly heavier bodyweights of the test rats.
In conclusion, as there were no unscheduled deaths or evidence of a toxic response following exposure of rats for 4 hours to a droplet aerosol generated from Mannanase, PPE 6432 at a chamber concentration of 0.45 mg enzyme concentrate dry matter/L in air, and the LC50 for mannanase is thus in excess of 0.45 mg enzyme concentrate dry matter/L.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Value:
- 450 mg/m³ air
- Quality of whole database:
- Toxicological data has been generated within the enzyme producing industry during the last 40 years. Substantial documentation on the safety of the production strains have been generated, and the enzyme test materials are thoroughly characterized. High quality studies for all relevant endpoints, in vivo studies as well as in vitro studies, show that industrial enzymes from well-known and well-characterized production strains have very similar safety profiles across the catalytic activities. Read-across can therefore be applied for the majority of toxicological endpoints. The database can thus be considered of high quality.
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- the study does not need to be conducted because the physicochemical and toxicological properties suggest no potential for a significant rate of absorption through the skin
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
In general, enzymes are of very low toxicity due to ready biodegradability and very low bioavailability. In traditional acute toxicity testing, mortality has been the endpoint. However, because enzymes show very low toxicity, extremely high doses that are far above human exposure levels typically have been applied. Therefore, acute toxicity studies are not considered to provide appropriate knowledge and are as such not a relevant test system for enzymes. Systemic exposure by the dermal route is unlikely based on the existing toxicokinetic knowledge of enzymes, which due to their relatively large molecular weight, are not expected to be absorbed through the skin (Basketter et al. 2008, Smith Pease et al. 2002). Therefore, it can be safely assumed that technical enzymes do not exert any acute dermal toxicity (Basketter et al 2012). This conclusion is confirmed by the toxicological data available. Sub-acute dermal toxicity studies with protease in rabbits (Novozymes, unpublished data) did not provide evidence for systemic effect to enzymes. This finding is confirmed by data from acute dermal toxicity studies (Novozymes, unpublished data) of other enzyme products in both rats and rabbits. None of these studies revealed any acute toxic effect through the dermal administration route. No clinical signs or adverse effects due to systemic exposure could be observed. Data waivers will further be established through exposure scenarios, i.e. no significant dermal exposure to consumers and professionals due to the toxicologically insignificant enzyme concentrations in end products and in the case of workers due to occupational hygiene measures associated with the prevention of respiratory allergy which includes protective clothing. In conclusion, toxicokinetic data together with evidence from animal studies and historical human experience derived from the use of detergent enzymes for decades confirm that exposure to technical enzymes will not result in any toxicologically relevant uptake by dermal route. Acute systemic exposure to a toxicologically significant amount of enzymes by this route can, therefore, be excluded and will further be prohibited by the obligatory setting of a DMEL value for enzymes, resulting in negligible exposure to enzymes (Basketter et al 2010). In vivo acute dermal toxicity studies will not add any value and cannot be expected to provide valuable knowledge and are considered scientifically and ethically unjustified. Therefore, in accordance with column 2 of REACH Annex VIII acute toxicity testing by the dermal route is inappropriate.
References:
- Basketter DA, English JS, Wakelin SH, White IR (2008). Enzymes, detergents and skin: facts and fantasies.Br. J. Dermatol., 158 (6):1177-1181.
- Smith Pease CK, White IR, Basketter DA (2002). Skin as a route of exposure to protein allergens.Clin. Exp. Dermatol., 27(4):296-300.
- Basketter D, Berg N, Broekhuizen C, Fieldsend M, Kirkwood S, Kluin C, Mathieu S, Rodriguez C (2012a). Enzymes in Cleaning Products: An Overview of Toxicological Properties and Risk Assessment/Management.Regul. Toxicol. Pharmacol., 64(1):117-123.
- Basketter DA, Broekhuizen C, Fieldsend M, Kirkwood S, Mascarenhas R, Maurer K, Pedersen C, Rodriguez C, Schiff HE (2010). Defining occupational and consumer exposure limits for enzyme protein respiratory allergens under REACH.Toxicology, 268(3):165-170.
Justification for classification or non-classification
Both acute oral and acute inhalation toxicity studies have been conducted testing mannanase. Both studies were conducted according to OECD guidelines and in compliance with GLP. The conclusions were that mannanase did not give rise to any toxicological concerns following either acute oral exposure (3.32 g total protein/kg bw) and inhalation exposure (0.45 mg enzyme concentrate dry matter/L). However, data is not suffecient for classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.